Stock comparison
Eli Lilly
LLY
Market cap
$1.01T
Sector
Healthcare
Overall winner
Eli Lilly
LLY 7–0 MRK
Merck &
MRK
Market cap
$298.33B
Sector
Healthcare
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
LLYvsMRK
73B
64C
88A
79B
87A
64C
75B
68B
77C
35D
86A
68C
77C
55D
Side-by-side metrics
| Metric | LLY | MRK |
|---|---|---|
| Market cap | $1.01T | $298.33B |
| P/E (TTM) | 39.1x | 33.2x |
| EV/EBIT | 36.3x | 14.5x |
| ROIC (TTM) | 32.06% | 13.34% |
| Gross margin | 83.51% | 75.91% |
| Net margin | 34.98% | 13.62% |
| Revenue CAGR 5y | 23.17% | 7.45% |
| EPS CAGR 5y | 40.81% | 9.06% |
| Debt / Equity | 1.4x | 1.1x |
| Dividend yield | 0.58% | 2.77% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- EPS CAGR 5y40.81%vs 9.06%+78%
- Market cap$1.01Tvs $298.33B+70%
- Revenue CAGR 5y23.17%vs 7.45%+68%
- Net margin34.98%vs 13.62%+61%
MRK leads on
- Dividend yield2.77%vs 0.58%+79%
- EV/EBIT14.5xvs 36.3x+60%
- Debt / Equity1.1xvs 1.4x+23%
- P/E (TTM)33.2xvs 39.1x+15%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.